BlueLinx Announces Preliminary Fourth Quarter and Full Year Results
Mar 15, 2016 11:30 am UTC| Business
- Best Fourth Quarter of Adjusted EBITDA since 2006 - - Adjusted EBITDA of $4.2 million, Up 121% from Q4 2014 -- Net Debt Down $23.6 million from Prior Year-End - ATLANTA, March 15, 2016 -- BlueLinx Holdings Inc....
Peak Resorts Reports Results for Third-Quarter and Nine-Months FY2016
Mar 15, 2016 11:30 am UTC| Business
WILDWOOD, Mo., March 15, 2016 -- Peak Resorts, Inc. (NASDAQ:SKIS), a leading owner and operator of high-quality, individually branded ski resorts in the U.S., today reported results for its fiscal 2016 third quarter and...
Mar 15, 2016 11:30 am UTC| Business
-CB-839 Combination Data submitted for Presentation at ASCO 2016 -IND to be submitted for Immuno-Oncology Candidate CB-1158 in mid-2016 -Calithera to Host Conference Call Today at 8:30 a.m. Eastern Time SOUTH SAN...
Mar 15, 2016 11:30 am UTC| Business
YARDLEY, Pa., March 15, 2016 -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced that the Company is now a member of the Blue Cross Blue...
Energy XXI Makes EPL Interest Payment and Enters Grace Period on EGC Interest Payments
Mar 15, 2016 11:15 am UTC| Business
HOUSTON, March 15, 2016 -- Energy XXI (NASDAQ:EXXI) today announced that it has made the interest payment due on its EPL Oil and Gas, Inc. 8.25% Senior Notes. This follows the Company’s decision to defer this interest...
JA Solar Announces Fourth Quarter and Fiscal Year 2015 Results
Mar 15, 2016 11:09 am UTC| Business
BEIJING, March 15, 2016 -- JA Solar Holdings Co., Ltd. (Nasdaq:JASO) ("JA Solar" or the "Company"), one of the world's largest manufacturers of high-performance solar power products, today announced its unaudited...
Myriad Presents Second Pivotal Validation Study for Its myPath® Melanoma Test
Mar 15, 2016 11:05 am UTC| Business
SALT LAKE CITY, March 15, 2016 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced the results from the second pivotal clinical validation study for the...